Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Neuroendocrine Tumor Treatment Market size was over USD 2.04 billion in 2024 and is projected to reach USD 5.62 billion by 2037, witnessing around 8.1% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of neuroendocrine tumor treatment is assessed at USD 2.17 billion.
The growth of the market is attributed to the increasing number of government cancer awareness campaigns. In addition, significant programs were launched or renewed on World Cancer Day to raise awareness of the gaps that exist and show what steps people can take to close these gaps. The World Health Organization (WHO) recently released a new Global Initiative Framework for Breast Cancer, setting out a plan to save more than 2 million lives from breast cancer by 2040.
In addition, the neuroendocrine tumor treatment market is expected to include increasing advances in neuroendocrine disease therapy and rapidly increasing investments. For example, a new peptide-receptor radionuclide therapy for late-stage neuroendocrine tumors (NETs) has been found to be more effective with fewer side effects, and the duration of treatment may be shorter compared to other anti-receptor therapies. It is a type of radiation treatment in which a radionuclide (a radioactive substance) is attached to a molecule that targets cells.
Neuroendocrine Tumor Treatment Sector: Growth Drivers and Challenges
Growth Drivers
-
Increasing Incidence of Neuroendocrine Cancer – On account of the increasing advancements in neuroendocrine tumors diagnosis, such as improved imaging tests and endoscopy, as well as growing awareness of these tumors, the neuroendocrine tumor treatment market is expected to expand more in the upcoming years. In the United States every year, five people out of every 100,000 are diagnosed with neuroendocrine tumors (NETs).
-
Rising Improvements in Technology for Treating Neuroendocrine Tumors – The application of modern technology to examine the underlying biology, develop of new therapeutics, and clinical trials to evaluate novel drugs is estimated to drive market growth. Further, the ability to employ single cell RNA sequencing to assess changes in gene expression at the single cell level is one of the most recent technological advancements (scRNA-Seq).
-
Growing Research & Development Investment – According to the most recent data, cancer research had reached one of its most productive and efficient peaks, with a flood of targeted medicines and licensed immunotherapies in various cancers in 2019.
Challenges
-
Expensive methods for treating neuroendocrine tumors - The rising frequency of neuroendocrine cancer might raise the average yearly health-care expenditure of managing a patient, which is one of the major factors predicted to slow down the neuroendocrine tumor treatment market growth. For instance, NET patients may develop functional syndromes such as carcinoid syndrome, which can have a major impact on quality of life and economic output.
-
Treatment-related side effects
-
Lack of knowledge among people
Neuroendocrine Tumor Treatment: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
8.1% |
|
Base Year Market Size (2024) |
USD 2.04 billion |
|
Forecast Year Market Size (2037) |
USD 5.62 billion |
|
Regional Scope |
|
Neuroendocrine Tumor Treatment Segmentation
Type (Somatostatin Analogs, Chemotherapy, Cancer Immunotherapy, and Targeted Therapy)
The somatostatin analogs segment in the neuroendocrine tumor treatment market is estimated to gain the largest revenue share in the year 2037. The growth of the segment can be attributed to the utilization of somatostatin analogs (SSAs) in treating neuroendocrine carcinoma, as they restrict tumor development, comorbidities, and biomarkers. Somatostatin analogues are medications that prevent your body from producing too many hormones made by some neuroendocrine tumors (NETs), and also aids in reducing carcinoid syndrome symptoms including diarrhoea and skin flushing. Moreover, it manages the emptying of the stomach and bowel. Somatostatin analogues are often injected into a muscle or beneath the skin.
End User (Hospitals, Clinics, and Others)
Neuroendocrine tumor treatment market from the hospital segment is expected to garner a significant share in the year 2037. Patients suffering from neuroendocrine tumor often visit hospitals for treatment, and it’s easier and more convenient for them as multiple options for NET diagnosis and other developed technologies are available on the hospital’s premises. They receive better care as nurses and doctors are easily accessible. On the other hand, the clinic segment is projected to witness a massive CAGR during the forecast period, owing to the presence of experienced surgeons and the availability of patient-centered treatment alternatives. Clinics provide healthcare that doesn't need an overnight stay in a hospital or other healthcare institution. This, as a result, is anticipated to create numerous opportunities for the growth of the segment in the market in the coming years.
Our in-depth analysis of the global neuroendocrine tumor treatment market includes the following segments:
|
Therapy |
|
|
End User |
|
|
Indication |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Neuroendocrine Tumor Treatment Industry – Regional Synopsis
North American Market Forecast
The neuroendocrine tumor treatment market in the North America region is projected to hold the largest market share of 38% by the end of 2037. The growth of the market can be attributed majorly to the high R&D spending by pharmaceutical corporations and regional governments. For instance, a number of programs for veterans and individuals with low income, including Medicaid and the Children's Health Insurance Program, are funded by the federal government. Further, the availability of advanced healthcare infrastructure in the region is also anticipated to contribute to the market growth in the region. In addition, the region's the productivity of health centers has increased as a result of the use of cutting-edge technologies such as data analytics, and AI in healthcare. More than 60% of Americans, private insurance serves as their primary form of health insurance.
European Market Statistics
The neuroendocrine tumor treatment market in the Europe region is projected to hold the second largest share during the forecast period. The growth of the market can be attributed majorly to the rising R&D expenditure, and strategic partnerships. For instance, companies located in the EU raised their R&D spending in the health and ICT sectors by 10.3% and 7.2%, respectively. In addition, Germany has a dominant position in the European neuroendocrine tumor market. Further, the rising rates of neuroendocrine tumors, the need for targeted drugs, and growing disposable income, are also anticipated to contribute to the market growth in the region. In addition, the Asia Pacific market is anticipated to witness significant growth in the coming years. As NETs are becoming more common in the region. Further, increased regional government spending to address the significant unmet clinical needs is also anticipated to support neuroendocrine tumor treatment market expansion.
Companies Dominating the Neuroendocrine Tumor Treatment Market
- BoehringerIngelheim International GmbH
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Hutchison MediPharma Limited,
- AVEO Oncology
- Pfizer, Inc.
- IpsenPharma
- Tarveda Therapeutics
- Progenics Pharmaceuticals
- Novartis AG
- Eli Lilly & Company
- Ipsen Pharma
Recent Developments
- Eli Lilly & Company to supply its human insulin active pharmaceutical ingredient (API) to IABL at a reduced cost in order to facilitate the manufacturing of insulin in Bangladesh.
- Boehringer Ingelheim teamed up with 3T Biosciences to identify and create cutting-edge cancer treatments to meet the significant unmet patient needs. Further, the collaboration will combine the industry-leading 3T-TRACE (T-Cell Receptor Antigen and Cross-Reactivity Engine) discovery platform from 3T Biosciences with Boehringer Ingelheim's two-pronged research approach combining cancer cell-directed and immune cell-targeting compounds.
Author Credits: Radhika Pawar
- Report ID: 3846
- Published Date: Nov 08, 2024
- Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
See our insights in action - schedule your demo now!
